These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 2306797)

  • 1. Efficacy and safety of high-dose cisplatin and cyclophosphamide with glutathione protection in the treatment of bulky advanced epithelial ovarian cancer.
    Di Re F; Bohm S; Oriana S; Spatti GB; Zunino F
    Cancer Chemother Pharmacol; 1990; 25(5):355-60. PubMed ID: 2306797
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-dose cisplatin and cyclophosphamide with glutathione in the treatment of advanced ovarian cancer.
    Di Re F; Bohm S; Oriana S; Spatti GB; Pirovano C; Tedeschi M; Zunino F
    Ann Oncol; 1993 Jan; 4(1):55-61. PubMed ID: 8435364
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dose intensification of platinum compounds with glutathione protection as induction chemotherapy for advanced ovarian carcinoma.
    Böhm S; Oriana S; Spatti G; Di Re F; Breasciani G; Pirovano C; Grosso I; Martini C; Caraceni A; Pilotti S; Zunino F
    Oncology; 1999; 57(2):115-20. PubMed ID: 10461057
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-dose cisplatin combination chemotherapy in the treatment of advanced epithelial ovarian carcinoma.
    Hainsworth JD; Burnett LS; Jones HW; Grosh WW; Johnson DH; Greco FA
    J Clin Oncol; 1990 Mar; 8(3):502-8. PubMed ID: 2407811
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase II study of combination chemotherapy in advanced ovarian carcinoma with cisplatin and cyclophosphamide plus reduced glutathione as potential protective agent against cisplatin toxicity.
    Locatelli MC; D'Antona A; Labianca R; Vinci M; Tedeschi M; Carcione R; Corbo A; Venturino P; Luporini G
    Tumori; 1993 Feb; 79(1):37-9. PubMed ID: 8497920
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advanced ovarian cancer: long-term results of treatment with intensive cisplatin-based chemotherapy of brief duration.
    Hainsworth JD; Grosh WW; Burnett LS; Jones HW; Wolff SN; Greco FA
    Ann Intern Med; 1988 Feb; 108(2):165-70. PubMed ID: 3124679
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative toxicity of cisplatin, carboplatin (CBDCA) and iproplatin (CHIP) in combination with cyclophosphamide in patients with advanced epithelial ovarian cancer.
    Anderson H; Wagstaff J; Crowther D; Swindell R; Lind MJ; McGregor J; Timms MS; Brown D; Palmer P
    Eur J Cancer Clin Oncol; 1988 Sep; 24(9):1471-9. PubMed ID: 3053207
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cisplatin and cyclophosphamide in early epithelial ovarian carcinoma.
    Chiara S; Conte PF; Bruzzone M; Falcone A; Sertoli MR; Carnino F; Mossetti C; Iura R; Durando C; Guercio E
    Chemioterapia; 1987 Oct; 6(5):380-3. PubMed ID: 3427698
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A feasibility study of cisplatin administration with low-volume hydration and glutathione protection in the treatment of ovarian carcinoma.
    Bohm S; Battista Spatti G; Di Re F; Oriana S; Pilotti S; Tedeschi M; Tognella S; Zunino F
    Anticancer Res; 1991; 11(4):1613-6. PubMed ID: 1746919
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dose intensive combination platinum and cyclophosphamide in the treatment of patients with advanced untreated epithelial ovarian cancer.
    Shapiro JD; Rothenberg ML; Sarosy GA; Steinberg SM; Adamo DO; Reed E; Ozols RF; Kohn EC
    Cancer; 1998 Nov; 83(9):1980-8. PubMed ID: 9806657
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized trial comparing two combination chemotherapy regimens (CHAP-5 v CP) in advanced ovarian carcinoma.
    Neijt JP; ten Bokkel Huinink WW; van der Burg ME; van Oosterom AT; Willemse PH; Heintz AP; van Lent M; Trimbos JB; Bouma J; Vermorken JB
    J Clin Oncol; 1987 Aug; 5(8):1157-68. PubMed ID: 3114434
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose-escalated paclitaxel in 1-hour infusion with a fixed dose of cisplatin in previously untreated advanced ovarian cancer: a phase II trial of the Spanish Group for Ovarian Cancer.
    Cervantes A; Mendiola C; del Campo JM; Massuti B; Casado A; Escobedo A; Moyano A; Ojeda B; Poveda A; Benito D
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-40-S15-43. PubMed ID: 9346221
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cisplatin plus etoposide as second-line treatment in advanced ovarian carcinoma.
    De Lena M; Lorusso V; Romito S
    Cancer Treat Rep; 1986 Jul; 70(7):893-5. PubMed ID: 3719581
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dose-intensive induction therapy with cyclophosphamide, cisplatin, and consolidative abdominal radiation in advanced-stage epithelial ovarian cancer.
    Rothenberg ML; Ozols RF; Glatstein E; Steinberg SM; Reed E; Young RC
    J Clin Oncol; 1992 May; 10(5):727-34. PubMed ID: 1569445
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-intensity intravenous cyclophosphamide and cisplatin, interim surgical debulking, and intraperitoneal cisplatin in advanced ovarian carcinoma: a pilot trial with ten-year follow-up.
    Shapiro F; Schneider J; Markman M; Reichman BS; Venkatraman E; Barakat R; Almadrones L; Spriggs D
    Gynecol Oncol; 1997 Oct; 67(1):39-45. PubMed ID: 9345354
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I/II study of paclitaxel, cisplatin, and cyclophosphamide in advanced ovarian carcinoma: preliminary results.
    Coeffic D; Benhammouda A; Antoine EC; Rixe O; Paraiso D; Auclerc G; Nizri D; Renody N; Grapin JP; Mularoni E; Rattini E; Soubrane C; Weil M; Mortier N; Khayat D
    Semin Oncol; 1996 Dec; 23(6 Suppl 15):5-8. PubMed ID: 8996589
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase I-II trial of intraperitoneal cisplatin and alpha-interferon in patients with persistent epithelial ovarian cancer.
    Berek JS; Welander C; Schink JC; Grossberg H; Montz FJ; Zigelboim J
    Gynecol Oncol; 1991 Mar; 40(3):237-43. PubMed ID: 2013446
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: initial and long term results--Eastern Cooperative Oncology Group Study E2878.
    Wadler S; Yeap B; Vogl S; Carbone P
    Cancer; 1996 Feb; 77(4):733-42. PubMed ID: 8616766
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical study of topotecan and cisplatin as first line chemotherapy in epithelial ovarian cancer].
    Meng LH; Kong BH; Zhang YZ; Yang XS; Wang LJ; Su SL; Jiang J; Cui BX; Wang B
    Zhonghua Fu Chan Ke Za Zhi; 2007 Oct; 42(10):683-7. PubMed ID: 18241544
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma. A Gynecologic Oncology Group Study.
    Omura G; Blessing JA; Ehrlich CE; Miller A; Yordan E; Creasman WT; Homesley HD
    Cancer; 1986 May; 57(9):1725-30. PubMed ID: 3513943
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.